(Q35163836)

6 August 2017

1 reference

title

Therapeutic drug monitoring in the treatment of HIV-infection (English)

1 reference

6 August 2017

John G Gerber

1

1 reference

6 August 2017

Edward P Acosta

series ordinal

2

1 reference

6 August 2017

publication date

1 July 2003

1 reference

Journal of Clinical Virology

6 August 2017

published in

1 reference

6 August 2017

volume

27

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

117-128

1 reference

Indinavir concentrations and antiviral effect

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

The role of therapeutic drug monitoring in treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Therapeutic drug monitoring in HIV infection: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Therapeutic drug monitoring--the need for audit?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Pros and cons of therapeutic drug monitoring of antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Audit of therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Human alpha-1-glycoprotein and its interactions with drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Comparative pharmacokinetics of antiviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Economic and outcome issues for therapeutic drug monitoring in medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2803%2900033-7

7 January 2021

10.1016/S1386-6532(03)00033-7

Identifiers

DOI

1 reference

6 August 2017

1 reference